Protein n-terminal de novo sequencing by position-selective dimethylation
US20230032607A1 · Regeneron Pharmaceuticals, Inc. · priority 2021
| Patent | US20230032607A1 ↗ |
| Status | Abandoned |
| Priority date | 2021-07-13 |
| Filed | 2022-07-12 |
| Published | 2023-02-02 |
| Assignee | Regeneron Pharmaceuticals, Inc. |
| Also published as | AU2022309876A1, CA3225730A1, CN117859065A, CO2024000351A2, EP4370928A1, IL309774A, JP2024526736A, KR20240032972A, WO2023287828A1 |
Abstract
The present invention generally pertains to methods of determining the amino acid sequence of a protein. In particular, the present invention pertains to the use of position-selective dimethylation and liquid chromatography-mass spectrometry to enhance the signal of N-terminal peptides and shift the signal of N-terminal peptides and corresponding b ions, thus facilitating a determination of the sequence of N-terminal peptides.
Why it is here
Regeneron: N-terminal sequencing by position-selective dimethylation, compared with a non-dimethylated control.
Inventors (2)
Yu Feng, Shunhai Wang
An inventor links to an author page only where the same person is evident, never on a name alone.
Cited by (1 patent families, 1 organisations)
- Vib Vzw company: US20230221329A1
Every family, of any applicant, that cites this one, as Google Patents lists them; an assignee is given its English name.